LIC trimmed its stake in Sun Pharmaceutical Industries from 5.53% to 5.32%, selling 50,35,809 shares.
A leading pharmaceutical manufacturer engaged in developing and marketing branded and generic formulations alongside Active Pharma Ingredients across global markets. The company operates multiple manufacturing facilities worldwide, serving customers through its extensive distribution network. Sun Pharma specializes in therapeutic areas including ophthalmology, cardiology, gastroenterology, and dermatology, combining research-driven innovation with broad-based generics production to serve patients in India and internationally.
India's largest domestic institutional investor with over Rs 56 lakh crore in total AUM, of which roughly Rs 15 lakh crore sits in listed equities. Holds stakes in virtually every major listed Indian company. When LIC builds or exits a position, it moves markets. Government-owned and mandated to invest policyholder funds in Indian equities and bonds, making it the ultimate long-only, long-term India bull.
